An array of treatments exists to manage SMH formed secondary to neovascular AMD, which includes the administration of only rTPA or anti-VEGF drugs, or performing vitrectomy with gas tamponade, or a combination of them. This evidence concerns the gene VEGFA and age-related macular degeneration.